Published in

International Union Against Tuberculosis and Lung Disease, International Journal of Tuberculosis and Lung Disease, 2(19), p. 151-156, 2015

DOI: 10.5588/ijtld.14.0200

Links

Tools

Export citation

Search in Google Scholar

Anti-tuberculosis drug resistance in Bangladesh: reflections from the first nationwide survey

Journal article published in 2015 by S. M. Mostafa Kamal, J. M. Aung †† K, Van Deun ¶¶ A, New Delhi India Who South East Asia Regional Office, † S Sultana, S. Sultana, Ka A. Hyder, Tm M. A. Rahman, ¶ T M. A. Rahman, A. Van Deun, M. D. K. A. Hyder, National Institute of Diseases of the Chest and Hospital (NIDCH) Dhaka Bangladesh National Tuberculosis Reference Laboratory, Directorate General of Health Services Ministry of Health & Family Welfare Dhaka Bangladesh National Tb Programme, Dhaka Bangladesh National Professional Offices-World Health Organization (NPO-Who), Tb Care-Ii Dhaka Bangladesh Npo-Who and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Journal Article ; OBJECTIVE: To determine the prevalence of tuberculosis (TB) drug resistance in Bangladesh. DESIGN: Weighted cluster sampling among smear-positive cases, and standard culture and drug susceptibility testing on solid medium were used. RESULTS: Of 1480 patients enrolled during 2011, 12 falsified multidrug-resistant TB (MDR-TB) patients were excluded. Analysis included 1340 cases (90.5% of those enrolled) with valid results and known treatment antecedents. Of 1049 new cases, 12.3% (95%CI 9.3-16.1) had strains resistant to any of the first-line drugs tested, and 1.4% (95%CI 0.7-2.5) were MDR-TB. Among the 291 previously treated cases, this was respectively 43.2% (95%CI 37.1-49.5) and 28.5% (95%CI 23.5-34.1). History of previous anti-tuberculosis treatment was the only predictive factor for first-line drug resistance (OR 34.9). Among the MDR-TB patients, 19.2% (95%CI 11.3-30.5; exclusively previously treated) also showed resistance to ofloxacin. Resistance to kanamycin was not detected. CONCLUSION: Although MDR-TB prevalence was relatively low, transmission of MDR-TB may be increasing in Bangladesh. MDR-TB with fluoroquinolone resistance is rapidly rising. Integrating the private sector should be made high priority given the excessive proportion of MDR-TB retreatment cases in large cities. TB control programmes and donors should avoid applying undue pressure towards meeting global targets, which can lead to corruption of data even in national surveys.